how do i use cryptocurrency, snippets

Haosen Intelligent: It has started to reserve technology in the field of humanoid robot application and equipment. Haosen Intelligent said on the investor interaction platform that the company, as an integrated supplier of intelligent production lines and intelligent equipment, has profound automation, intelligence, informationization and flexibility in the fields of automobile and industrial manufacturing. At present, we have started to reserve technology in the field of humanoid robot application and equipment, which can provide integrated solutions for humanoid robots and AMR robots, and simultaneously lay out humanoid robot production lines and test benches.The Hang Seng Index of Hong Kong stocks opened higher by 0.46%, the index of state-owned enterprises rose by 0.51%, and the branch index rose by 0.46%.YTO Express invested 30 million yuan in Hengyang City to set up a new company. The enterprise search APP shows that recently, Hengyang YTO Express Co., Ltd. was established, with the legal representative of Sun Kai and the registered capital of 30 million yuan. Its business scope includes: general cargo warehousing services; Domestic freight forwarder; Storage equipment rental service. Enterprise equity penetration shows that the company is indirectly wholly-owned by YTO Express.

Facewall Intelligence has received a new round of financing of several hundred million yuan. Recently, Facewall Intelligence has completed a new round of financing of several hundred million yuan. This round of financing was jointly led by Loongson Venture Capital, Dinghui Baifu, Zhongguancun Science City Fund and Safran Investment Fund, and Beijing Artificial Intelligence Industry Investment Fund and Zero2IPO followed suit.The US investment bank explained the downward adjustment of India's economic growth forecast: Based on the short-term economic slowdown and influenced by multiple internal and external factors, according to the Indian media "QRIUS", Uppsala Chachar, chief Indian economist of Morgan Stanley, the US investment bank, predicted that India's GDP growth in fiscal year 2025-2026 would be 6.5%. According to India's Economic Times, at the beginning of this month, Morgan Stanley has lowered India's GDP growth forecast for fiscal year 2024-2025 from the previous 6.7% to 6.3%.Guojin Securities: There is a certain room for the valuation of brokers to rise, focusing on two main lines. Guojin Securities said that looking forward to 2025, liquidity is expected to be further relaxed, market stability will be improved, and a solid market bottom will be built. The improvement of economic fundamentals will be confirmed, and the stock market is expected to go further, which will benefit the valuation and performance of brokerage sectors. Under the background of previous liquidity easing, the valuation of securities firms has expanded to above 1.9X, and the current valuation of securities firms is 1.6X, which has a certain room for growth on the whole. Pay attention to the main line of strong beta business and the main line of mergers and acquisitions.

Sora concept stocks fell, Huayang Lianzhong fell, Easy Point World, Fushi Holdings fell more than 8%, and Wanxing Technology fell nearly 5%.Ma Zhixin, the chief financial officer of Nissan, was informed that he would lead the business in China again. According to the Nikkei News, the board of directors of Nissan Motor Co., Ltd. decided to re-appoint Stephen Ma to take charge of the business in China, and JÉRÉMIE PAPIN, the chairman of Nissan Americas Company, will replace Ma Zhixin as the chief financial officer. In 2012, Ma Zhixin served as vice president of Dongfeng Co., Ltd., then transferred back to Nissan headquarters in 2018 and was promoted to chief financial officer the following year.Lee Ka Chiu John: The Hong Kong SAR Government hopes to set up a food and drug administration in the future. Lee Ka Chiu John, Chief Executive of the Hong Kong Special Administrative Region (HKSAR) said today (11th) that the SAR Government hopes to set up a food and drug administration in the long run to give full play to the advantages of clinical trials with the Mainland.